Trials / Completed
CompletedNCT03575065
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, open-label, multi-center study of BGB-290 administered orally (PO) twice daily (BID) in adult Chinese patients with advanced HER2(-) breast cancer harboring germline BRCA mutation, which have progressed despite standard therapy, or for which no standard therapy exists.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-290 | Administered orally |
Timeline
- Start date
- 2018-06-22
- Primary completion
- 2020-10-09
- Completion
- 2021-04-14
- First posted
- 2018-07-02
- Last updated
- 2024-10-26
- Results posted
- 2022-09-07
Locations
20 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03575065. Inclusion in this directory is not an endorsement.